Open Accessβ-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models
Author(s) -
Gianina Demarchi,
S Valla,
Sofía Perrone,
Agustina Chimento,
N. Bonadeo,
Daiana Luján Vitale,
Fiorella Mercedes Spinelli,
Andrés Cervio,
Gustavo Sevlever,
Laura Alaniz,
Silvia Berner,
Carolina Cristina
Publication year - 2022
Publication title -
tumor biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1423-0380
pISSN - 1010-4283
DOI - 10.3233/tub-211500
Subject(s) - prolactinoma , wnt signaling pathway , temozolomide , catenin , cyclin d1 , cancer research , pituitary tumors , prolactin cell , medicine , apoptosis , pituitary adenoma , pituitary neoplasm , cell cycle , prolactin , endocrinology , adenoma , biology , pituitary gland , signal transduction , cancer , microbiology and biotechnology , glioma , biochemistry , hormone
Prolactinomas are the most frequent pituitary tumor subtype. Despite most of them respond to medical treatment, a proportion are resistant and become a challenge in clinical management. Wnt/β-Catenin pathway has been implicated in several cancers including pituitary tumors and other sellar region malignancies. Interestingly, Wnt/β-Catenin inhibition augments the cytotoxicity of the chemotherapeutic agent Temozolomide (TMZ) in different cancers. TMZ is now being implemented as rescue therapy for aggressive pituitary adenoma treatment. However, the molecular mechanisms associated with TMZ action in pituitary tumors remain unclear.